Global auto injectors market is mainly driven by increase in incidence of the life threatening conditions such as anaphylaxis, multiple sclerosis and other food allergies that need an emergency medication. In addition, advancements in auto injectors like introduction of jet injectors, growing home healthcare segment, and increase in demand for the self-injectors expected to bolster the market growth. Furthermore, new formulations, new drug delivery systems, and advancements in targeted drug delivery systems, favourable government policies are expected to boost the auto injectors market. Many biologics are administered as intravenously hence, many manufacturers are adopting auto injectors for the life-saving biologics. However, stringent regulatory requirements, recent product recalls, and presence of substitute products are hampering the global auto injectors market.A sample of this report is available upon request @
[URL]https://www.precisionbusinessinsights.com/market-reports/global-auto-injectors-market/#ulp-4H8Z4LpNMLEuOnnx[/URL]
Auto injectors market has been segmented based on type, technology, usability, distribution channel, and application
Based on type, auto injectors market is segmented into
Fillable
Pre-Filled
Based on technology, auto injectors market is segmented into
Automated
Manual
Based on usability, auto injectors market is segmented into
Disposable
Reusable
Based on application, auto injectors market is segmented into
Anaphylaxis
Rheumatoid Arthritis
Multiple Sclerosis
Others
Based on distribution channel, auto injectors market is segmented into
Hospitals
Retail Pharmacies
Online Pharmacies
Others
To view TOC of this report is available upon request @
[URL]https://www.precisionbusinessinsights.com/market-reports/global-auto-injectors-market/#ulp-c654SbFYO64MsOhu[/URL]
Auto injector manufacturers are diversifying the product portfolio by introducing low-cost auto injector products, incorporate advanced features into products, and with new product launches. For instance, Mylan N.V. introduced generic version of epipen by reducing the price to half of its original product price. Initial pack of two was sold at US$ 600 until December 2016 that will be sold at US$ 300 from January 2017. Bayer AG introduced betaconnect, an electronic auto injector to treat relapsing-remitting multiple sclerosis in 2016. Companies are actively involved in collaborations, and taking license agreements for auto injector’s technology. In September 2016, Aptar Pharma (AptarGroup, Inc.) collaborated with Becton, Dickinson and Company (BD) to develop auto injector using prefillable syringes from BD and Aptar Pharma’s two-step auto-injector technology.
Need more information about this report @
[URL]https://www.precisionbusinessinsights.com/market-reports/global-auto-injectors-market/#ulp-14mlyhjMGhVjZqa3[/URL]
Some of the players in auto injectors market are Becton, Dickinson and Company (U.S), Sanofi (France), Pfizer, Inc. (U.S.), Mylan N.V. (U.S.), Novartis AG (Switzerland), Bayer AG (Switzerland) , Johnson and Johnson Services Inc., (Janssen Global Services) (U.S.), Antares Pharma, Inc. (U.S.), Amgen Inc. (U.S.) and Eli Lilly and Company (U.S) to name a few.
Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free(US): +1-866-598-1553